Yizong Tongluo formula attenuates idiopathic pulmonary fibrosis and inflammatory injury by inhibiting HIF-1α/LSH/SCD1-mediated ferroptosis
Frontiers in Immunology · 2026
DOI: 10.3389/fimmu.2026.1760615 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Immunology, 2026. Verfasst von Xin Ma und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Fourth Clinical Medical College, Xinjiang Medical University, Urumqi, China. Hauptthemen laut MEDLINE: Ferroptosis, Hypoxia-Inducible Factor 1, alpha Subunit, Idiopathic Pulmonary Fibrosis, Drugs, Chinese Herbal. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Idiopathic pulmonary fibrosis (IPF) is a progressive disease characterized by chronic inflammation, aberrant tissue remodeling, and hypoxia. In traditional Chinese medicine (TCM), it is classified as Qi deficiency–blood stasis syndrome. The mechanism of Yizong Tongluo Formula (YZTLF), a Traditional Chinese Medicine (TCM) herbal formulation and effective pharmaceutical agent for the clinical treatment of IPF, remains unclear.
Methods
This study investigated the immunomodulatory and anti-fibrotic mechanisms of YZTLF for this IPF subtype by focusing on the HIF-1α/LSH/SCD1 signaling pathway and ferroptosis-induced inflammatory injury. We began by analyzing clinical samples from IPF patients with Qi deficiency and blood stasis was conducted to assess the signalling axis and ferroptosis markers. Molecular and histological analyzes were performed using TGF-β-treated MRC-5 fibroblast cells and a bleomycin-induced rat model of pulmonary fibrosis.
Results
Clinical analysis revealed a dysregulation of the HIF-1α/LSH/SCD1 axis and altered levels of ferroptosis markers in patients. In vitro , YZTLF significantly downregulated HIF-1α and LSH expression while upregulating SCD1 ( p < 0.01 ). Importantly, the treatment markedly suppressed ferroptosis, as evidenced by reduced intracellular Fe 2+ and ACSL4 levels alongside increased Glutathione Peroxidase 4 (GPX4) and GSH expression ( p < 0.01 ). It also inhibited TGF-β-induced fibroblast activation, significantly decreasing α-SMA and Collagen I protein levels ( p < 0.01 ). In vivo , the YZTLF treatment attenuated bleomycin-induced lung injury, reduced inflammatory cell infiltration, preserved alveolar architecture, and reduced collagen deposition, alongside normalizing of HIF-1α/LSH/SCD1 signaling and restoration of antioxidant levels.
Conclusion
These findings indicate that YZTLF mitigates IPF progression in the context of Qi deficiency and blood stasis by suppressing ferroptosis-driven inflammation and remodeling the hypoxic microenvironment via the HIF-1α/LSH/SCD1 pathway. This provides a mechanism-based rationale for its use in this TCM-defined IPF subtype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Fourth Clinical Medical College, Xinjiang Medical University, Urumqi, China.
- Department of Respiration, Traditional Chinese Medicine Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China.
Zitieren
APA
Ma, X., Wang, X., Jiang, D., Tuerxun, Y., Tao, S., Li, F., Wei, Y., Yang, L., Xi, L., & Wang, L. (2026). Yizong Tongluo formula attenuates idiopathic pulmonary fibrosis and inflammatory injury by inhibiting HIF-1α/LSH/SCD1-mediated ferroptosis. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1760615
Vancouver
Ma X, Wang X, Jiang D, Tuerxun Y, Tao S, Li F, et al. Yizong Tongluo formula attenuates idiopathic pulmonary fibrosis and inflammatory injury by inhibiting HIF-1α/LSH/SCD1-mediated ferroptosis. Frontiers in Immunology. 2026. doi:10.3389/fimmu.2026.1760615
BibTeX
@article{Ma2026,
author = {Ma, Xin and Wang, Xin and Jiang, Daobin and Tuerxun, Yiminnuer and Tao, Siming and Li, Fengsen and Wei, Yanrong and Yang, Liu and Xi, Lei and Wang, Ling},
title = {Yizong Tongluo formula attenuates idiopathic pulmonary fibrosis and inflammatory injury by inhibiting HIF-1α/LSH/SCD1-mediated ferroptosis},
journal = {Frontiers in Immunology},
year = {2026},
doi = {10.3389/fimmu.2026.1760615}
}
EUVIMED